Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z. Li A, et al. Among authors: okimoto t. J Immunother Cancer. 2022 Sep;10(9):e005433. doi: 10.1136/jitc-2022-005433. J Immunother Cancer. 2022. PMID: 36096533 Free PMC article.
An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients.
Nguyen LTH, Zhang J, Rima XY, Wang X, Kwak KJ, Okimoto T, Amann J, Yoon MJ, Shukuya T, Chiang CL, Walters N, Ma Y, Belcher D, Li H, Palmer AF, Carbone DP, Lee LJ, Reátegui E. Nguyen LTH, et al. Among authors: okimoto t. J Extracell Vesicles. 2022 Sep;11(9):e12258. doi: 10.1002/jev2.12258. J Extracell Vesicles. 2022. PMID: 36093740 Free PMC article.
SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling.
Zhao B, Gong W, Ma A, Chen J, Velegraki M, Dong H, Liu Z, Wang L, Okimoto T, Jones DM, Lei YL, Long M, Oestreich KJ, Ma Q, Xin G, Carbone DP, He K, Li Z, Wen H. Zhao B, et al. Among authors: okimoto t. Nat Immunol. 2022 Nov;23(11):1588-1599. doi: 10.1038/s41590-022-01326-8. Epub 2022 Oct 20. Nat Immunol. 2022. PMID: 36266363 Free PMC article.
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T, Kenmotsu H, Harada H, Ohde Y, Chiba Y, Haratani K, Okimoto T, Sakamoto T, Wakuda K, Ito K, Uemura T, Sakata S, Kogure Y, Nishimura Y, Nakagawa K, Yamamoto N. Miyawaki T, et al. Among authors: okimoto t. BMC Cancer. 2021 Oct 18;21(1):1121. doi: 10.1186/s12885-021-08851-z. BMC Cancer. 2021. PMID: 34663250 Free PMC article. Clinical Trial.
381 results